Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$114.94 USD

114.94
125,471

-0.30 (-0.26%)

Updated May 15, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome

Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's Why You Should Buy ShockWave Medical (SWAV) Stock

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

NuVasive (NUVA) to Expand in APAC With New Experience Center

NuVasive's (NUVA) Singapore Experience Center will complement the flagship Experience Centers in San Diego and the New York metropolitan area.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.

BD's (BDX) New Combination Test to Boost Patient Outcome

BD's (BDX) latest combination test is expected to speed up the detection of the infection-causing viruses, thereby accelerating the implementation of the appropriate treatment plan.

Intuitive (ISRG) New Lung Biopsy Imaging Technology Gets FDA Nod

The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.

Catalent (CTLT) Expands Packaging Capabilities at Japan Facility

Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

Integer Holdings (ITGR) continues to gain momentum from improving non-medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.

Cardinal Health (CAH) Ties Up to Deliver Products Via Drones

Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.

3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?

Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y

Patterson Companies' (PDCO) fiscal fourth-quarter 2022 results benefit from strength in the Dental and Animal Health segments.

Align (ALGN) Gains From Increased Case Shipment Amid FX Woes

Align Technology's (ALGN) focus on expanding its global operations, both in existing and emerging international markets, raises optimism.

Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal

Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.

Here's Why Investors Should Retain Syneos Health (SYNH) For Now

Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.

3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care

Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

Stryker (SYK) to Boost Presence in China Via Digital Healthcare

Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.

Here's Why Investors Should Retain CVS Health (CVS) For Now

Investors are optimistic about CVS Health's (CVS) robust revenue growth across its operating segments.

Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.